President and CEO
Arturo received his Bachelor’s Degree in Economics from the University of Connecticut and has been involved in the management of photonics research companies for his entire career. He is a founder of Ciencia and became the company’s president in 2006. Under his leadership, Ciencia has established GC- FP technology as a valuable research platform and has led the refinement of this technology into the Centinela platform.
CTO
Dr. Guignon is the Chief Technology Officer and the Director of Engineering at Ciencia, Inc. Dr. Guignon received his Ph.D. in Biological Engineering from the University of Connecticut. Prior to joining Ciencia he was the Director of Clinical Engineering at the University of Connecticut Health Center. Dr. Guignon is responsible for the design, development, and production of the earliest GC-FP instrumentation. He is also the principal investigator for all of Ciencia’s SBIR/STTR awards since 2006. Dr. Guignon is the author of over twenty peer- reviewed publications and patents.
Senior Scientist
Dr. Page is a researcher and consultant at Ciencia, Inc. Dr. Page received his B.S. in Chemistry from Vassar College and his M.D. from the University of Connecticut School of Medicine. He completed an Internal Medicine residency at Brown University. Dr. Page brings clinical expertise to Ciencia’s projects and assists with instrument design and strategy. Dr. Page shares papers and patents with Dr. Guignon and Ciencia’s extended team.
VP of Commercial Operations
David has held senior leadership roles with innovative digital health, diagnostics, and analytics companies for more than 15 years, including two which were acquired by leaders in their respective industries. He most recently served as Brown University’s Senior Director of Technology Transfer for four years, where he created commercial relationships for promising life sciences technology created within Brown labs. He received his MBA from Dartmouth College, and his AB Magna Cum Laude from Bowdoin College.
Ciencia has established close relationships with academics who use the Centinela platform to perform assays that would otherwise be prohibitively expensive using traditional methods. These research efforts validated our approach and enabled our current initiative in clinical diagnostics. Key collaborations include:
Professor of Physics at the University of Connecticut. Dr. Gibson has designed the streamlined GC-FP optical system currently in use in the Centinela platform.
Professor of Nanobioscience at SUNY Polytechnic Institute and collaborator on Lyme Disease and COVID-19 antibody studies.
Professor of Immunology at the University of Connecticut and early adopter of GC-FP technology. Dr. Lynes has explored diverse applications of our technology such as MIS-C, type I diabetes, rheumatoid arthritis, and toxicant exposure on stem cells.
Professor and Chair of Environmental Health Sciences at the University of Albany School of Public Health and the Wadsworth Center. Dr. Lawrence has explored GC-FP technology for the detection of circulating breast cancer tumor cells, effects of toxicants, and cytokine analysis.
